The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001063303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/07/2026
Date registered
Help: Date registered
27/08/2026
Date last updated
Help: Date last updated
27/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Oral versus intravenous beta-blocker for pre-scan heart-rate control in adults undergoing computed tomography coronary angiography (CTCA): effect on time to scan - a randomised controlled trial,
Scientific title
Oral versus intravenous beta-blocker for pre-scan heart-rate control in adults undergoing computed tomography coronary angiography (CTCA): effect on time to scan - a randomised controlled trial
Additional trial identifiers [1] 318059 0
RES-26-0000-434A
Universal Trial Number (UTN)
Trial acronym
BEAT-CT
Related trial records

Health condition
Health condition(s) studied:
Coronary artery disease 343071 0
Condition category
Condition code
Cardiovascular 339168 339168 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intravenous metoprolol protocol for pre-scan heart rate control (Group 2, intervention arm)

Participants allocated to Group 2 receive intravenous metoprolol tartrate for heart rate control immediately prior to CTCA. The protocol is adapted from the Barts Heart Centre intravenous beta-blockade protocol.

Metoprolol tartrate is administered intravenously in 5 mg increments. Each 5 mg dose is administered as a slow intravenous bolus, with heart rate and blood pressure reassessed 2 minutes after each dose before any further dose is given; the complete titration typically takes 10 to 15 minutes. Dosing is titrated to a target heart rate of 65 beats per minute or lower, up to a maximum cumulative dose of 30 mg (a maximum of six 5 mg doses). Heart rate, non-invasive blood pressure (NIBP) and mean arterial pressure (MAP) are recorded at baseline and after each incremental dose. Further doses are withheld once the target heart rate is achieved, the maximum 30 mg cumulative dose is reached, or a pre-specified safety threshold is met (systolic NIBP less than or equal to 89 mmHg or MAP less than or equal to 59 mmHg), consistent with the thresholds applied in Group 1.

The intervention is delivered by a trained cardiac imaging nurse, credentialed in intravenous beta-blocker administration, under the supervision of the cardiologist or radiologist sub-investigator, with continuous cardiac monitoring in place.

Both groups additionally receive sublingual glyceryl trinitrate 300–600 micrograms immediately prior to image acquisition for coronary vasodilation, in accordance with standard CTCA practice, provided systolic blood pressure remains above the safety threshold described above and no contraindication exists. Glyceryl trinitrate is administered identically in both arms and does not form part of the randomised comparison.

Mode of administration: Intravenous.

Timing and duration: Administered on the day of the scan. Intravenous administration commences approximately 15 to 30 minutes prior to planned image acquisition, in the period immediately preceding the scan; administration concludes when the target heart rate is achieved, the maximum cumulative dose is reached, or a safety threshold is met (as described above).

Tailoring: Dosing is titrated to each participant's heart rate response, as described above, rather than fixed.

Adherence and fidelity: As administration is clinician-delivered and directly observed, each incremental dose and its corresponding heart rate and blood pressure, together with the total dose administered, are recorded contemporaneously on the study data collection sheet, allowing protocol fidelity to be verified.
Intervention code [1] 334935 0
Treatment: Drugs
Description of the comparator or control
Comparator name: Oral metoprolol protocol (Group 1, comparator arm)

Participants allocated to Group 1 receive oral beta-blockade for heart rate control prior to computed tomography coronary angiography (CTCA), reflecting current standard pre-scan practice at the Victorian Heart Hospital. The protocol is delivered in the Cardiac Imaging Centre by trained cardiac imaging nurses and radiographers under the supervision of the supervising radiologist and cardiologist.
Dose and titration: Metoprolol succinate is administered orally at a dose of 25 mg to 200 mg, given 30 to 90 minutes prior to planned image acquisition, titrated to a target heart rate of 65 beats per minute or lower.
For patients whose heart rate is 70bpm or greater, 10mg oral ivabradine is administered immediately in combination with oral metoprolol succinate 100mg. If following 30 minutes, the heart rate remains 70 beats per minute or greater, a further dose of 100mg oral metoprolol succinate is administered. Following this, if after 30 minutes the target heart rate of 65 beats per minute or lower has not been achieved, intravenous metoprolol tartrate rescue is permitted.
Intravenous metoprolol tartrate rescue is administered in 5 mg increments up to a maximum cumulative dose of 20 mg (a maximum of four 5 mg doses), with heart rate and blood pressure reassessed after each increment before any further dose is given. Intravenous rescue is commenced only after maximal permitted oral therapy has been administered. IV metoprolol is administered on the CT scan gantry - with heart rate, non-invasive blood pressure and mean arterial pressure recordings at baseline, following each oral dose, and after each intravenous rescue increment – as has been described in the IV dosing arm protocol.
Mode of administration: Oral, with intravenous rescue where required.
Timing and duration: Administered on the day of the scan, in the period preceding image acquisition; dosing concludes when the target heart rate is achieved, the permitted maximum is reached, or a pre-specified safety threshold is met (systolic NIBP less than 90 mmHg or MAP less than 60 mmHg).
Tailoring: Dosing of oral and intravenous metoprolol is titrated to each participant's heart rate response and haemodynamic parameters as described above, by a trained cardiac imaging nurse and as directed by the supervising Cardiologist or Radiologist.

Adherence and fidelity: Doses administered, the corresponding heart rate and blood pressure, and any intravenous rescue given are recorded contemporaneously on the study data collection sheet, allowing protocol fidelity to be verified.
Control group
Active

Outcomes
Primary outcome [1] 346406 0
Time to scan, defined as the interval (in minutes) from commencement of the allocated heart-rate lowering intervention to commencement of computed tomography coronary angiography (CTCA) image acquisition
Timepoint [1] 346406 0
On the day of the scan; the interval is measured once per participant during the single study visit.
Secondary outcome [1] 465740 0
Image quality: percentage of non-satisfactory images in each arm
Timepoint [1] 465740 0
At completion of the scan, on the day of the scan
Secondary outcome [2] 466553 0
Frequency of systolic phase imaging
Timepoint [2] 466553 0
At scan acquisition
Secondary outcome [3] 466554 0
Frequency of scan cancellation
Timepoint [3] 466554 0
At patient cancellation, as decided by reporting clinician
Secondary outcome [4] 466555 0
Radiation dose (from widened acquisition window)
Timepoint [4] 466555 0
At completion of scan
Secondary outcome [5] 466556 0
Rate of adverse events in each arm
Timepoint [5] 466556 0
Time of adverse event, type of adverse event. Documented in data collection sheet

Eligibility
Key inclusion criteria
Adult outpatients aged 18 years or older
Presenting for computed tomography coronary angiography (CTCA)
In sinus rhythm
Resting heart rate greater than 60 beats per minute (bpm)
Systolic non-invasive blood pressure (NIBP) of 100 mmHg or greater
Able to lie supine and raise both arms above the head
Able to understand and follow instructions, including lying motionless and performing a breath-hold when requested
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Regular pharmacological treatment including beta-blockers or verapamil, or self-administration of beta-blockers as premedication prior to arrival
Resting heart rate of 100 bpm or greater
Marked bradycardia, or heart rate already within the range for diagnostic imaging (less than 60 bpm)
Systolic non-invasive blood pressure (NIBP) of 100 mmHg or less at baseline
Arrhythmia - current or history of atrioventricular block, sinus bradycardia, or atrial fibrillation (unless a permanent pacemaker is in situ)
Permanent pacemaker in situ
Aged under 18 years
Pregnant or breastfeeding
Allergy to contrast media
Known allergy or hypersensitivity to beta-blockers, including bronchospasm
Contraindication to nitroglycerin (glyceryl trinitrate)
Claustrophobia or anxiety requiring anxiolytic
Obesity: girth 80 cm or greater, or weight 135 kg or greater
Renal insufficiency: eGFR 60 mL/min/1.73m² or less
Previous percutaneous coronary intervention or coronary artery bypass grafting
Unstable angina
Poorly controlled or brittle asthma (refer to cardiologist; documented hospital admission in the preceding 6–12 months by record or patient report)
History of severe asthma, chronic obstructive pulmonary disease (COPD), severe aortic valve stenosis, restrictive cardiomyopathy, or severe hepatic impairment
Severe left ventricular dysfunction, ejection fraction 35% or less
History of cardiomyopathy with no echocardiogram in the previous 2 years
Use of phosphodiesterase inhibitors (e.g. sildenafil) in the previous 24 hours

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed using sequentially numbered, opaque, sealed envelopes. Each envelope will be opened only after a participant has been enrolled and their eligibility confirmed, so that the enrolling investigator cannot predict the group to which the next participant will be assigned.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
permuted block randomisation
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The sample size was calculated for the primary outcome of time to scan (minutes). Based on unpublished data from a recent study at the Victorian Heart Hospital, the mean time to scan for patients undergoing computed tomography coronary angiography (CTCA) with oral with or without intravenous ß-blockade is 73 minutes. A reduction of 20 minutes was considered the minimum clinically meaningful difference to detect with a primarily intravenous metoprolol strategy.

Assuming a two-sided alpha of 0.05 and 80% power, and using analysis of covariance (ANCOVA) to adjust for baseline covariates (including baseline heart rate), 64 participants per group are required to detect this difference. ANCOVA is expected to increase statistical power by reducing residual variance through covariate adjustment. To allow for attrition, including withdrawals and protocol deviations, the target was inflated to 100 participants per group, giving a total recruitment target of 200 participants.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29937 0
Victorian Heart Hospital - Clayton
Recruitment postcode(s) [1] 46299 0
3168 - Clayton

Funding & Sponsors
Funding source category [1] 322621 0
Self funded/Unfunded
Name [1] 322621 0
Country [1] 322621 0
Primary sponsor type
Individual
Name
Rebecca Woodley - Monash Health
Address
Country
Australia
Secondary sponsor category [1] 325540 0
None
Name [1] 325540 0
Address [1] 325540 0
Country [1] 325540 0
Other collaborator category [1] 284048 0
Individual
Name [1] 284048 0
Sean Tan - Monash Health
Address [1] 284048 0
Country [1] 284048 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321082 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 321082 0
Ethics committee country [1] 321082 0
Australia
Date submitted for ethics approval [1] 321082 0
04/06/2026
Approval date [1] 321082 0
07/07/2026
Ethics approval number [1] 321082 0
128763

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152594 0
Mrs Rebecca Woodley
Address 152594 0
Ground Floor Cardiac Imaging, 631 Clayton Road, Clayton, 3168, Victoria
Country 152594 0
Australia
Phone 152594 0
+61425821676
Fax 152594 0
Email 152594 0
Contact person for public queries
Name 152595 0
Rebecca Woodley
Address 152595 0
Ground Floor Cardiac Imaging, Victorian Heart Hospital, 631 Clayton Road, Clayton, 3168, Victoria
Country 152595 0
Australia
Phone 152595 0
+61425821676
Fax 152595 0
Email 152595 0
Contact person for scientific queries
Name 152596 0
Rebecca Woodley
Address 152596 0
Ground Floor Cardiac Imaging, Victorian Heart Hospital, 631 Clayton Road, Clayton, 3168, Victoria
Country 152596 0
Australia
Phone 152596 0
+61425821676
Fax 152596 0
Email 152596 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.